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Background: International disease management guidelines recommend the regular assessment of depression and
anxiety in heart failure patients. Currently there is little data on the effect of screening for depression and anxiety on
the quality of life and the prognosis of heart failure (HF). We will investigate the association between the recognition
of current depression/anxiety by the general practitioner (GP) and the quality of life and the patients’ prognosis.
Methods/Design: In this multicenter, prospective, observational study 3,950 patients with HF are recruited by
general practices in Germany. The patients fill out questionnaires at baseline and 12-month follow-up. At baseline
the GPs are interviewed regarding the somatic and psychological comorbidities of their patients. During the
follow-up assessment, data on hospitalization and mortality are provided by the general practice. Based on baseline
data, the patients are allocated into three observation groups: HF patients with depression and/or anxiety
recognized by their GP (P+/+), those with depression and/or anxiety not recognized (P+/−) and patients without
depression and/or anxiety (P−/−). We will perform multivariate regression models to investigate the influence of the
recognition of depression and/or anxiety on quality of life at 12 month follow-up, as well as its influences on the
prognosis (hospital admission, mortality).
Discussion: We will display the frequency of GP-acknowledged depression and anxiety and the frequency of
installed therapeutic strategies. We will also describe the frequency of depression and anxiety missed by the GP and
the resulting treatment gap. Effects of correctly acknowledged and missed depression/anxiety on outcome, also in
comparison to the outcome of subjects without depression/anxiety will be addressed. In case results suggest a
treatment gap of depression/anxiety in patients with HF, the results of this study will provide methodological advice
for the efficient planning of further interventional research.
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Heart failure (HF) is an increasingly prevalent condition
with high mortality and morbidity rates [1]. Dyspnoea,
oedema, fluid retention, pulmonary congestion and fa-
tigue comprise common symptoms of HF. Although not
necessarily jointly present within each individual patient,
these symptoms exert substantial detrimental influences
on functional status and quality of life [1-3].Psychosocial risk factors
Various studies established the important influence of
psychosocial factors on the course and prognosis of HF
patients [4,5]. Depression affects 20–40% of patients
with HF [6] and is 4–5 times more common in HF than
in the general population [7]. Depressive symptoms are
associated with a 2–3 fold increased mortality risk and
were shown to act independently of biological (classical)
risk factors [8,9]. Symptoms of anxiety are reported for
38-70% of patients with congestive heart failure [10].
For this reason national and international HF guidelines
recommend the regular assessment of depression [11-15]
and anxiety [11,12,15] in heart failure patients. How-
ever, even though recent evidence suggests that patients
screened positive for depression have an increased risk
for hospitalization, emergency department visits and
mortality [16,17], there is no data available on the trans-
formation of these recommendations into routine care
of HF patients.
Different aspects of psychosocial health (e.g. depression,
anxiety, social support) are highly interrelated. It is still
unclear which factor or component may independently
affect the prognosis of HF patients [5]. We are aware of
two randomised controlled trials investigating the effects
of selective serotonin re-uptake inhibition on morbidity,
mortality and mood in depressed patients with HF [18,19].
While the MOOD-HF study is still on-going [18], the
SADHART-CHF trial concluded that the lack of effects of
sertraline, compared to placebo treatment, may be due to
the effect of nurse support within the placebo group,
where depression scores improved significantly [19]. How-
ever, these trials focus on pharmacological interventions
in a tertiary care setting. There are no interventional stud-
ies in primary care examining complex interventions such
as screening for depression/anxiety (and subsequent treat-
ment initiated by the general practitioner) in HF patients.
There are also no studies that examined the effect of rec-
ognition and subsequent treatment of depression/anxiety
initiated by the general practitioner (GP) once depression
and or anxiety have been recognized. Therefore, it will
be important to determine whether there is a need for
interventional research targeting the effect of treating
depression and anxiety on the prognosis of HF in patients
with HF in primary care.Recognition of depression and anxiety
In Germany, the recognition rate of depression in the
primary care sector has been reported at 74% [20]. Rec-
ognition rates among HF patients are likely to be lower
because of the symptom overlap of non-specific HF
symptoms and symptoms of depression. We are aware of
one study investigating recognition rates of depression
and anxiety in ambulatory HF patients. This study found
that 42.5% of patients screened positive for depression
and/or anxiety also had a diagnosis of depression or
anxiety in their medical records [21]. However, that
study almost exclusively included men (98.7%) and did
not investigate the prognostic implication of recognition/
treatment of depression/anxiety. Despite the purported
clinical relevance of depression and anxiety, no interven-
tion studies investigated the effects of depression and
anxiety modification on the prognosis of HF patients
in primary care settings. Further, the evidence base to
support such trials is slim because so far there is no
observational data underlining an association between
recognition of depression and anxiety and the depression/
anxiety-outcome [22], nor data underlining the cardiovas-
cular outcome in primary care patients with HF [23-25].
As a result of these considerations, the aim of the
study is to evaluate the state of psychosocial health care
(recognized and unrecognized depression/anxiety and
subsequent treatment) and its influence on health related
quality of life and prognosis in primary care patients
with HF.
Given that the prevalence rates of depression in HF
patients vary due to differences in and the threshold levels
of the assessment tools used, appropriate cut-off values
for self-administered instruments measuring anxiety/
depression in HF patients will be derived in a sub-study.
Methods/Design
The study is designed as a multicenter, prospective, obser-
vational study investigating 3,950 primary care patients
with HF in Germany. The following research questions
will be addressed:
 How many patients with HF suffer from depression
and/or anxiety?
 How are the recognition rates of depression and/or
anxiety by general practitioners (GPs)?
 How often are which measures taken by the GP
when depression and/or anxiety are recognized?
 Is there an association between the presence of
depression and/or anxiety and quality of life and HF
prognosis (hospital admittance and mortality risk)?
 Is there an association between the recognition of
present depression/anxiety by the GP and quality of
life and HF prognosis (mortality, hospital
admissions)?
Table 1 Inclusion and exclusion criteria
Observation
group 1
(P+/+)
Observation
group 2
P(+/−)
Observation
group 3
P(−/−)
Inclusion Criteria
Informed consent ✓ ✓ ✓
Aged 18 years and older ✓ ✓ ✓
Diagnosis of heart failure
within the last 5 years,
validated by the GP on
basis of his medical records
✓ ✓ ✓
At least one contact with
the participating GP within
the last 6 month
✓ ✓ ✓
Depression and/or anxiety ✓ ✓
Recognition of existing
depression and/or anxiety
by the GP
✓
Exclusion Criteria
Diagnosis of dementia
given by the GP
✓ ✓ ✓
Not a regular patient of the
participating GP’s practice
✓ ✓ ✓
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and with failure to initiate adequate interventions
(pharmacological or psychotherapeutical)?
 Is there an association between the presence and the
recognition of depression/anxiety by the GP and
health care aspects (e.g. frequency of contacts with
the GP)?
Recruitment
Recruitment takes place in two steps: First: primary care
practices are recruited; and second: the participating
GPs invite their patients to participate in the study. Two
study centers, Hamburg and Würzburg, recruit general
practices in four recruitment regions: Hamburg, Kiel,
Lübeck (northern Germany) and Würzburg (southern
Germany). The recruitment of the primary care practices
began in April 2012 and will last until January 2014. All
primary care practices in Hamburg, Kiel, Lübeck and
Würzburg and within a 50 km radius of these cities, (to
include urban and rural areas), receive a written invita-
tion to participate in the study. If not responding to the
invitation, study staff contacts each general practitioner
by phone.
In a second step, participating GPs apply the following
search criteria to identify eligible patients from the elec-
tronic records: age 18 and above, last consultation
within the last six months, and any diagnosis of heart
failure (ICD-Codes beginning with I50, I11.0, I13.0,
I13.2) documented within the last 5 years. Out of all
patients, who meet the mentioned criteria those who
passed away since the last consultation or suffer from
dementia are excluded (for a complete list of all inclusion
and exclusion criteria see Table 1).
All eligible patients are invited to participate in the
study through a letter from their GP. This letter includes
all written information regarding the study, as well as a
consent form. Beside a study description, the patient
information covers procedures of the study, data collec-
tion, processing and storage, as well as possibilities for
withdrawal of consent. A phone number for contacting
the study staff with questions and for further information
is provided with the information package. The informed
consent form is already provided with a randomly
assigned ID number.
In case of interest, the patient sends the signed,
informed consent form to the recruiting study center
via a prepaid and pre-addressed envelope. The first patient
was included in July 2012; the recruitment of patients will
last until January 2014.
Study endpoints
The primary outcome of this longitudinal study is the
quality of life after 12-months of follow-up. The secondary
outcome is the prognosis of heart failure in terms ofhospital admissions and mortality risk within the 12-
month follow-up period. Group comparisons will contrast
patients with depression and/or anxiety recognized by the
GP (observation group 1: P(+/+)), patients with depression
and/or anxiety not recognized by the GP (observation
group 2: P(+/−)) and patients without depression and/
or anxiety whose GPs did not diagnose any depression
or anxiety (observation group 3: P(−/−)). For further
information see Table 1.
Data collection
Data is collected at the baseline assessment and at the
follow-up assessment 12 months later. In the baseline
assessment the patient receives a self-administered ques-
tionnaire by mail (see Table 2), as well as a free return
envelope. Five days after the questionnaire is sent the
patients receive a reminder by mail. Based on the in-
formation provided in the questionnaire, the patients
are assigned to one of three observation groups. For
more details see section Recognition of depression
and anxiety. The GP of each patient assigned to one of
the observation groups is interviewed by study staff in
a telephone-interview. During the interview the GP has
access to all patient data in his or her medical records.
The questions regarding depression and anxiety are
collected along with a comprehensive list of further
comorbidities (see Table 2).
Since diagnosis of heart failure will be obtained from
the electronic patient records, we will double-check that
the heart failure diagnosis is correct at the beginning of
the telephone interview with the GP. After validating the
Table 2 Data collection
BASELINE
Patients: Self-administered
questionnaires (by mail)
Depression Patient Health Questionnaire 9-item
Subscale Depression (PHQ-9) [26-28]/
Hospital Anxiety and Depression
Scale [29,30] – Subscale Depression
(HADS-D)/PROMIS Depression
Scale [31,32]
Anxiety Patient Health Questionnaire 7-item
Subscale Generalized Anxiety Disorder
Assessment (GAD-7) [33-35]/Hospital
Anxiety and Depression Scale [29,30] –
subscale anxiety (HADS-A)/PROMIS
Anxiety Scale [31,32]
Treatment of Anxiety and
Depression
Medication intake/Utilization of
psychotherapy or other therapies (e.g.
music therapy, occupational therapy,
relaxation training)
Social support Lubben Social Network Scale (LSNS)
[36]/ENRICHED Social Support
Instrument (ESSI) [37]
Stress Patient Health Questionnaire -
Subscale Stress (PHQ-D) [26,38]
Compliance Morisky Medication Adherence Scale
(MMAS-8) [39-41]
Quality of life EQ-5D-5 L [42]
Self-efficacy General Self-efficacy Scale [43]
Lifestyle Salt restriction: Do you pay attention
to your diet?/Fluid intake: How much
do you drink daily?/Weight control:
How often do you weigh yourself?/
Vaccination: Did you receive a flu
shot within the last year? Have you
been vaccinated against
pneumonia?/Alcohol intake: At
occasions you drink alcohol, how
much alcohol do you consume on
average?/Smoking status and
cigarette consumption: If you smoke
occasionally or regularly: How much
do you consume on average?
Physical Activity/Capacity How often do you engage in
physical activity? Based on Verghese
[44]/Self-rated physical capacity
according to NYHA class
Socio-economic status Household income per capita
Sociodemographic data Gender/Age/Height/Weight/Type of
insurance/Marital status/Status of
living/ Nursing care/Employment
status/ Education [45]/Migration
status/ Citizenship
Contact to the GP Last contact/Frequency of contacts
within the last 6 month/Years of
being patient of the actual GP
GPs: Telephone-interview with
insight in the medical record
Validation of heart-failure
diagnosis
Does the patient have heart failure?/
Severity level according to New York
Heart Association (NYHA) class/
Ejection fraction
Table 2 Data collection (Continued)
Size of practice Number of GPs in the practice/
Practice type (single practice/practice
sharing/group practice)/Number of
patients insured by the statutory
health insurance per quarter/
Percentage of private patients
Familiarity with the patient Are you the regular GP of the
patient?/How well do you know the
patient? (Scale 1 to 10)
Comorbidity Charlson Comorbidity Index [46]/
Which additional diseases does the
patient have?
Depression/Anxiety Does the patient have any
symptomatology of depression/
anxiety? If yes, please specify/Had
the patient any symptomatology of
depression/anxiety in the past?
Measures taken if depression/
anxiety is recognized
What treatment have you
prompted?
Treatment of heart failure What difficulties have you
encountered when treating the
heart failure in this patient? Have
there been any reasons to deviate
from the recommended
pharmacological treatment?
Sociodemographic data of
the GP
Age/Gender/Years of practice/
Speciality/Additional trainings
12-MONTH FOLLOW-UP
Patients: Self-administered
questionnaire (by mail)
All measures according to baseline; additional data:
Hospital admission within
the last 12 month
Number of Hospital Admissions/Date
of admission/Length of stay/
Admission diagnosis/Emergency vs.
pre-scheduled hospitalization
Change of GP Did you change your GP within the
last 12 month? If yes: How many
months ago did you change your GP?
GP: Information from medical
records (provided by phone)
Survival Mortality within the last 12 month/
Date of death/Course of death
Hospital Admission Number of Hospital Admissions/Date
of Admission/Length of stay/
Admission diagnosis/Emergency vs.
pre-scheduled hospitalization/
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heart failure according to New York Heart Association
(NYHA) functional class. For all further information
collected see Table 2.
At the 12-month follow-up assessment the patient re-
ceives a second self-administered questionnaire by mail,
while data in the general practice will be extracted from
the medical records of the practice and are provided by
either the GP or practice staff over the phone. For fur-
ther details regarding the contents of the data collection
please refer to Table 2.
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A sub-study is performed by the University of Göttingen
Medical Center, which is not involved in the main study.
The aim of this sub-study is to identify appropriate cut-
points and combinations of established self-rating scales
for depression and anxiety in primary care patients with
heart failure. For this purpose, a subsample of 190
patients with symptomatic heart failure completes the
Hospital Anxiety and Depression Scale (HADS) [29,30],
Patient Health Questionnaire 9-item Subscale Depression
(PHQ-9) [26-28] and Patient Health Questionnaire 7-
item Subscale Generalized Anxiety Disorder Assessment
(GAD-7) [33-35], as well as selected items from PROMIS
Depression and Anxiety scales [31,32], and undergoes the
Structured Clinical Interview for DSM-IV (SCID) [47].
The SCID is a structured one-hour face-to-face diagnostic
interview by a trained psychologist with a patient. It is the
reference standard for the diagnosis of depression and
anxiety disorders in research projects [48]. In this study
SCID interviews are performed by psychologists (blind to
patients’ self-ratings), to identify the relative value and
optimal clinical cut-points for the identification of primary
care patients with HF and comorbid depression or anxiety
disorders. Different cut-points on the self-rated PHQ-9,
GAD-7, and HADS are compared by Receiver Operating
Characteristics for the detection of different classes of
SCID-based diagnoses. If appropriate, exploratory ana-
lyses are attempted to optimise case finding algorithms
based on combinations of the self-rating scales or their
individual items. Previous research has shown that such
analyses are feasible with the designated sample size for
the sub-study [49,50].
In the main study, the case finding algorithm (identified
in the SCID sub-study) is applied on the information given
in the baseline questionnaire. Therefore, the questionnaire
includes the same self-administered instruments as used
in the sub-study (HADS, PHQ-9 and GAD-7, PROMISFigure 1 Baseline and follow-up assessment.Depression and Anxiety scales). Depending on the
algorithm from the sub-study, the patients are classified
as patients with depression and/or anxiety or patients
without depression and/or anxiety. Due to the work
load, we do not interview the GPs of 25% of the patients
without depression and anxiety by phone. Therefore, for
each practice 75% of all patients without depression
and/or anxiety (group P-) are randomly selected for
telephone interviews with the GP and assigned to the
observation group 3 (P-).
After baseline assessment, GP interviews will be avail-
able for each patient assigned to one of the three
observation groups. For further detail see Figure 1.
The 75% randomly selected patients without depression
and/or anxiety provides a higher number of patients in the
observation group 3 (P−/−) than the power calculation
suggests (see section Sample size calculation). The higher
number is chosen for quality assurance. A group of
patients without depression and anxiety which is too
small would reveal the focus on depression and anxiety
in this study. Therefore the proportion of patients with
depression and/or anxiety and without depression/anxiety
will be 1:3 in each interview.
Symptoms of anxiety and depression are addressed
within a full list of somatic comorbidities, introduced
by the somatic conditions of the Charlson Comorbidity
Index [46] and followed by a question concerning any
further comorbidity, which has not been addressed in
the list before. The focus on depression and anxiety
within this study is not revealed to the GPs. During the
interview the GPs have full access to all patient data
within their electronic records. The recognition of
depression and/or anxiety is operationalized as the GP’s
judgement in the telephone interview as to whether or
not the patient displays symptoms of depression and/
or anxiety. If the GP states that the patient displays
symptoms, the GP is asked if he or she judges this as a
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not severe enough for a diagnosis.
In a next step, patient information from the ques-
tionnaire and GP judgment regarding depression and
anxiety are matched and the patients are allocated to
one of the following groups:
 Observation group 1 (P +/+): All patients with
depression and/or anxiety whose depression and/or
anxiety has been recognized by the GP
 Observation group 2 (P +/−): All patients with
depression and/or anxiety whose depression and/or
anxiety has not been recognized by the GP
 Observation group 3: P (−/−) Sample of patients
without depression and anxiety who were randomly
selected for telephone interview. In the interview
the GPs did not diagnosed any depression or
anxiety.
Patients without depression and anxiety whose GP
nevertheless diagnosed depression or anxiety P(−/+) will
be considered separately.Sample size calculation
Given a prevalence of psychosocial risk factors (depression,
anxiety or both) in HF patients from general practices of
20% [6] and a recognition rate of 75% [20], we aim for a
sample that provides us a minimum power of 80% to de-
tect a minimum difference of at least any 5 points on the
EQ-5D visual analogue scale (EQ-VAS) [42] with α = 0.05.
Therefore, a sample of 672 participants with depression
and/or anxiety is needed, of whom 504 have depression
and/or anxiety recognized by their GP (P+/+) and 168
with depression and/or anxiety not recognized by their
GP (P+/−).
Given an estimated participation rate of 40%, a return
rate of the baseline questionnaire of 90% and a loss to
follow-up rate of 15% a total of 10,973 patients with heart
failure are needed to be invited into the study by their GP
(see Figure 2).
For a comparison with heart failure patients without
psychosocial risk factors, a random sample of N = 2,370
of those who completed the baseline questionnaire but
were not identified to have depression and/or anxiety
will be drawn (P−/−). Taking a loss to follow-up rate of
15% into account, a total of 2,015 patients with heart
failure but without depression and/or anxiety at base-
line will be included in the analyses. A minimum num-
ber of 118 patients at the follow-up assessment would
already provide a power of 80% to detect differences
between the groups (P+/+, P+/− and P−/−) of at least any
5 points on the EQ-5D visual analogue scale (EQ-VAS)
[42] with α = 0.05.Quality assurance
The study is centrally coordinated by the study center
Hamburg. All processes regarding the recruitment of GP
practices and patients will be parallelized between both
recruiting centers. To avoid selection bias, patients with
heart failure are selected electronically from the medical
records. We use validated instruments for the assessment
of baseline and follow-up characteristics. All study staff
conducting telephone interviews have been trained. All
interviewers are blind regarding the group the patient
has been allocated to.
For the data collection from GPs, depression and
anxiety is offered in a full list of other potential comor-
bidities to minimise social desirability bias and to mask
the focus on anxiety and depression. Additionally, the
GP is interviewed regarding patients with and without
depression and/or anxiety. The 75% of eligible patients
in the observation group 3 exceed the number required by
the power calculation and are suggested to be sufficient to
detract from the focus on patients with depression and
anxiety. Questionnaires are electronically imported into
the database. All import data is double-checked before
analysis. Analyses are performed anonymously.
Data protection
All patients automatically receive a pseudonym which is
printed on the consent form included in the study infor-
mation they obtain. The data of the consent form is en-
tered into a password protected database which is secured
on an additional password protected USB stick stored in a
lockable cabinet together with the consent forms.
All data assessed in the baseline and follow-up assess-
ment is documented pseudonymously. The data is elec-
tronically entered in a local password-secured database.
As soon as the data entry of the follow-up assessment is
completed the allocation key will be deleted and all data
will be anonymous.
Description of risks
It is not expected that the participation in the study will
expose the patients to any risks.
Ethics approval
The study is conducted in compliance with the Declaration
of Helsinki. The study protocol was approved by the local
Ethics Committees (Medical Association of Hamburg,
Approval No. PV3889; Ethics Committee of the Medical
Faculty of the University of Würzburg, Approval No.
125/12, Ethics Committee at the University of Göttingen
Medical Center, Approval No. 19/8/11).
Data analysis
The prevalence of comorbidities in patients with HF
and difficulties in the treatment of patients with HF will
Figure 2 Sample size considerations.
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recognition/non-recognition of psychosocial risk factors
in primary care HF patients and its impact on the study
endpoints will be analysed. In a first step we will compare
quality of life, hospitalisation and mortality after a 1-year
follow-up period between HF patients with depression/
anxiety (P+/+ and P+/−) and those without (P−/−).
In the second step we will compare quality of life,
hospitalisation and mortality after a 1-year follow-up
period between HF patients with depression and/or
anxiety recognized by their GP (P+/+) and those with
depression and/or anxiety not recognized (P+/−). We
will perform multivariate regression models taking theconfounding effects (e.g. comorbidity, sociodemographics,
type of treatment for depression/anxiety and heart failure
severity) into account.
In a third step we will compare several types of treat-
ment for psychosocial risk factors and their potential
effects on quality of life, hospitalisation and mortality
after a 1-year follow-up period.
We will compare the information concerning the
treatment of psychosocial risk factors gathered from pa-
tients with that gathered from GPs to evaluate potential
differences (e.g. due to treatment initiated by other
healthcare providers than the GP). We will re-run the
analyses of the third step for information gathered from
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separately.
For binary outcomes (hospitalization, survival after
1 year), chi-squared tests will be used. For continuous
outcomes (quality of life, survival time), t-tests or non-
parametric rank tests will be used. Multivariate linear
regression analyses will be performed for the total number
of hospitalized days, Cox regression and Kaplan-Meier
curves for time to hospitalization survival time. Multi-
variate linear regression will be used for quality of life.
Discussion
This is the first study conducted to investigate the effect
of the recognition of depression and anxiety and the
subsequently initiated treatment by the GP on the quality
of life and the prognosis of heart failure in HF patients in
primary care. The results are expected to glean important
insights into the care for HF patients in primary care.
Expected implications for practice
We will be able to show how many heart failure patients
in primary care suffer from depression and anxiety.
We will display the frequency of GP-acknowledged
depression/anxiety and the factors which may facilitate
and exacerbate the recognition. Based on these results,
patient characteristics which exacerbate recognition
will be reported to GPs. Such knowledge will assist the
GP in judging which HF patient may benefit from
additional attention paid to symptoms of depression
and anxiety. The frequency of installed therapeutic
strategies and the impact of the different therapeutic
approaches on quality of life and heart failure prognosis
found in this study will be displayed. These results will be
provided to GPs and will give a first orientation of which
therapeutic strategies might be helpful for HF patients,
not only to reduce depression, but also to improve their
quality of life and prognosis of heart failure.
Expected implications for health policy
Public health planners are in need of numbers such as
frequency of depression and anxiety as well as frequency
of different treatment options substantiating the decision
process of resource allocation. For the health planners we
will describe the frequency of depression and/or anxiety
missed by GPs and the potential treatment gap.
Such a treatment gap with respect to psychosocial
problems in HF patients is currently unproven but needs
to be assumed if preliminary findings are transferred onto
the general population. If so, more resources should be
spent on investigating effective treatments.
For these investigations the differential effects of
correctly acknowledged and missed depression and/or
anxiety on outcome, also in comparison to the outcome
of subjects without depression and/or anxiety, will help tobetter understand how health care for HF patients needs
to be improved and which treatment might be effective.
We will be able to present evidence to what extent the
recognition of depression and/or anxiety through screen-
ing for depression and anxiety is mandatory for HF
patients, as already recommended in clinical guidelines.
Expected implications for research
The results of this study will help to generate hypoth-
eses regarding effective treatment of depression and
anxiety and the potential effects on the quality of life
and prognosis in patients with HF. In a next step these
hypotheses can be tested by intervention studies. The
case-finding algorithm to identify HF patients with
depression and anxiety obtained from the sub-study
could be recommended for further observational and
intervention studies in HF patients and is likely to
reduce the huge variation of reported prevalence rates.
In addition, this study will provide methodological support
for efficient planning of further interventional research.
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